Latest news from jCyte on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/jcyte-inc-identifies-retinitis-pigmentosa-patients-most-likely-to-respond-in-planned-pivotal-study-with-jcell-therapy/?sc=rsin /articles/jcyte-inc-identifies-retinitis-pigmentosa-patients-most-likely-to-respond-in-planned-pivotal-study-with-jcell-therapy/?sc=rsin Mon, 03 May 2021 08:00:00 EST jCyte's presentation at ARVO 2021, demonstrated that retinitis pigmentosa patients treated with the 6 million cell dose of jCell therapy had significant gains in a broad range of visual function tests - BCVA, visual field (KVF), contrast sensitivity (CS), and low luminance mobility (LLMT) - all which measure important and different aspects of functional vision. jCyte also engaged the Cleveland Clinic to identify an anatomical biomarker for patient response to jCell therapy in retinitis pigmentosa, which will help guide the upcoming pivotal study. jCyte /articles/jcyte-presents-results-of-clinical-testing-in-retinitis-pigmentosa2/?sc=rsin /articles/jcyte-presents-results-of-clinical-testing-in-retinitis-pigmentosa2/?sc=rsin Fri, 15 Dec 2017 08:30:48 EST In a phase 1/2a study jCyte's investigational therapy, jCell, showed a good safety profile and indications of potential benefit for patients with retinitis pigmentosa jCyte /articles/jcyte-receives-regenerative-medicine-advanced-therapy-designation/?sc=rsin /articles/jcyte-receives-regenerative-medicine-advanced-therapy-designation/?sc=rsin Tue, 02 May 2017 08:00:10 EST Cell therapy company jCyte has received Regenerative Medicine Advanced Therapy designation from the FDA for their developmental retinitis pigmentosa therapy. jCyte /articles/powered-by-cirm-grant-jcyte-launches-new-clinical-trial/?sc=rsin /articles/powered-by-cirm-grant-jcyte-launches-new-clinical-trial/?sc=rsin Wed, 19 Apr 2017 07:00:25 EST Cell-based therapy company jCyte is launching a Phase 2b clinical trial to study the effectiveness of its developmental therapy for retinitis pigmentosa. jCyte /articles/jcyte-completes-enrollment-for-phase-i-iia-safety-trial/?sc=rsin /articles/jcyte-completes-enrollment-for-phase-i-iia-safety-trial/?sc=rsin Mon, 28 Nov 2016 10:00:42 EST Regenerative medicine company jCyte has completed enrollment in a phase I/IIa trial studying the safety of its stem cell therapy for retinitis pigmentosa. Early results are promising. jCyte /articles/early-trial-results-support-the-safety-of-cell-based-retinitis-pigmentosa-treatment/?sc=rsin /articles/early-trial-results-support-the-safety-of-cell-based-retinitis-pigmentosa-treatment/?sc=rsin Thu, 14 Jul 2016 17:05:07 EST Regenerative medicine company jCyte and the Sue & Bill Gross Stem Cell Research Center at the University of California, Irvine report that their investigational therapy for retinitis pigmentosa (RP) has demonstrated a favorable safety and tolerability profile in an ongoing Phase I/II clinical trial. jCyte